Infectious disease
Stephane Bancel, chief executive officer of Moderna, told analysts and journalists at a Wall Street Journal’s Tech Live event on Monday that the FDA requires enough safety and efficacy data, and he believes that they will have that in the later part of November.
In a challenge trial, people are given a vaccine then intentionally dosed with the virus or bacteria that causes the disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Dr. Monica Gandhi, MD, an infectious diseases doctor and professor of medicine at UC San Francisco, poses the hypothesis that masks and other social distancing measures may reduce the viral inoculum – or amount – of the SARS-CoV-2 we contract.
They believe that by inhibiting factor D, it would reduce the inflammatory reactions that make COVID-19 so deadly.
The grant was awarded by the U.S. Dept. of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA).
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Pfizer will not seek Emergency Use Authorization for its COVID-19 vaccine until the end of November even if the readout from a Phase III study expected later this month is positive.
The WHO’s SOLIDARITY clinical trial evaluated remdesivir and three other drugs in 11,266 hospitalized COVID-19 patients and found that none of the drugs “substantially affected mortality” or decreased the need to ventilate patients.
Putin touts efficacy and safety of new vaccine without the data to back him up.
PRESS RELEASES